I am a Healthcare Professional

These posters, oral presentations, and/or abstracts are provided for medical and scientific purposes only, they may include investigational use or agents that are not approved by health authorities. The information presented is not meant to convey conclusions of safety or effectiveness prior to any regulatory approval from a health authority.

Sanofi does not recommend the use of any products in a manner inconsistent with that described in the full prescribing information. Please refer to the prescribing information in your country of practice for any medicinal products mentioned.

Availability of posters and/or abstracts on this site will conform with conference embargo policies. By selecting “Accept”, you are certifying that you are a Healthcare Professional.

Reject

ISTH 2025 | Jun 21, 2025 - Jun 25, 2025

Rare Blood Disorders

Some of the most serious unmet patient needs today are in the field of hematology, and Sanofi is committed to breaking barriers through groundbreaking science to significantly improve the health and lives of people with rare blood disorders around the world.

More about Rare Blood Disorders

Available rooms
1 of 1

  • Hemophilia

    Hemophilia A and B are rare genetic blood disorders, characterized by excessive or uncontrolled bleeding into joints, tissues, and body cavities, which can be life-threatening or lead to disability.

  • ITP

    Immune thrombocytopenia (ITP) is an autoimmune disorder characterized by the destruction of healthy platelets that increases a patient’s risk of bleeding.

  • aTTP

    Acquired thrombotic thrombocytopenic purpura (aTTP) is a rare blood disorder that develops when the immune system stops a key enzyme (ADAMTS13) from working properly. Without this protein, the body creates too many blood clots.